The goal of this \[study type: clinical trial\] is to \[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\] in \[describe participant population/primary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\]. The main question\[s\] it aims to answer \[is/are\]:
* Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period?
* What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients?
Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given\]:
* Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks
* Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion